![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Lenacapavir - recently published phase 2 safety/efficacy
in treatment-naives; at CROI; + Preclinical Studies of
New Prevention Interventions at CROI
|
|
|
New PrEP Studies - Lenacapavir; Adolescent Girls, Young Women - (12/12/22)
Update on Gilead's HIV Prevention Trials - (12/12/22)
CROI: Lenacapavir Protects Against Rectal SHIV Acquisition in Macaque Model - (02/24/23)
CROI 2023: Lenacapavir Treatment, Prevention - (03/01/23)
CROI: Long-Acting Lenacapavir in a Combination Regimen for Treatment Naïve PWH: Week 80 - (02/25/23)
CROI: Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH - (02/24/23)
CROI: Lenacapavir Protects Against Rectal SHIV Acquisition in Macaque Model - (02/24/23)
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
Lenacapavir in first-line therapy - (01/27/23)
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (01/27/23)
LENACAPAVIR INHIBITS VIRION MATURATION BY BLOCKING FORMATION OF CAPSID PENTAMERS (ABSTRACT 100)
Mamuka Kvaratskhelia
University of Colorado, Aurora, CO, United States
https://www.croiwebcasts.org/console/player/51541?mediaType=slideVideo&
LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV (ABSTRACT 193)
Joseph J. Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
https://www.croiwebcasts.org/console/player/51834?mediaType=slideVideo&
CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/22/23)
-------------------------------------
presented in this Themed Discussion: PRECLINICAL STUDIES OF NEW PREVENTION
INTERVENTIONS
SESSION OVERVIEW-PRECLINICAL STUDIES OF NEW PREVENTION INTERVENTIONS
Ariane van der Straten
University of California San Francisco, Kensington, CA, United States
https://www.croiwebcasts.org/console/player/51899?mediaType=slideVideo&
LENACAPAVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL (ABSTRACT 992)
Elena Bekerman
Gilead Sciences, Inc, Foster City, CA, United States
https://www.croiwebcasts.org/console/player/51900?mediaType=slideVideo&
EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS (ABSTRACT 990)
Natalia Makarova
Centers for Disease Control and Prevention, Atlanta, GA, United States
https://www.croiwebcasts.org/console/player/51901?mediaType=slideVideo&
![0417231](../images/041723/041723-2/0417231.gif)
ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES
CROI 2023: EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS
CROI 2023: Good Rectal TAF/EVG Levels With Rectal Inserts in HIV-Negative Men and Women
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission
VAGINAL PREP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES (ABSTRACT 989)
Michele B. Daly
Centers for Disease Control and Prevention, Atlanta, GA, United States
https://www.croiwebcasts.org/console/player/51902?mediaType=slideVideo&
CROI: Vaginal PrEP Efficacy of Biodegradable Islatravir Implants in Macaques Islatravir Implant Protects Macaques From Vaginal SHIV Infection
ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV (ABSTRACT 165)
Alessandro Grattoni
Houston Methodist Research Institute, Houston, TX, United States
https://www.croiwebcasts.org/console/player/51726?mediaType=slideVideo&
CROI:ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV
PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTEGRAVIR IN SITU FORMING IMPLANT (ABSTRACT 991)
Isabella Young
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
https://www.croiwebcasts.org/console/player/51903?mediaType=slideVideo&
![0417232](../images/041723/041723-2/0417232.gif)
CROI: Pharmacokinetics and X-ray Imaging of Long-acting Cabotegravir In Situ Forming Implant
![0417233](../images/041723/041723-2/0417233.gif)
DISCUSSION WITH ANSWERS TO AUDIENCE QUESTIONS
Ariane van der Straten
University of California San Francisco, Kensington, CA, United States
https://www.croiwebcasts.org/console/player/51904?mediaType=slideVideo&
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|